The prognostic significance of DNA flow cytometry in breast cancer: results from 881 patients treated in a single centre.
暂无分享,去创建一个
C. E. Gillett | M. A. Richards | W. Gregory | R. Camplejohn | D. Barnes | C. Gillett | R. Millis | M. Richards | C. M. Ash | W. M. Gregory | R. S. Camplejohn | B. Raikundalia | D. M. Barnes | R. R. Millis | B. Raikundalia | DM Barnes | C E Gillett | WM Gregory | MA Richards | Rr Millis | C. Ash | RS Camplejohn | Richard Dunbleby
[1] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[2] R. K. Knight,et al. CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER , 1983, The Lancet.
[3] R. Camplejohn,et al. Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer. , 1987, British Journal of Cancer.
[4] M. Palmer,et al. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. , 1988, British Journal of Cancer.
[5] H. Joensuu,et al. The prognostic significance of nuclear DNA content in invasive breast cancer--a study with long-term follow-up. , 1989, British Journal of Cancer.
[6] R. Camplejohn,et al. Measurement of S-phase fractions in lymphoid tissue comparing fresh versus paraffin-embedded tissue and 4',6'-diamidino-2 phenylindole dihydrochloride versus propidium iodide staining. , 1989, Cytometry.
[7] L L Vindeløv,et al. A review of techniques and results obtained in one laboratory by an integrated system of methods designed for routine clinical flow cytometric DNA analysis. , 1990, Cytometry.
[8] W. McGuire,et al. Ploidy, proliferative activity and prognosis. DNA flow cytometry of solid tumors , 1990, Cancer.
[9] M. Fernö,et al. Indicators of prognosis in node-negative breast cancer. , 1990, The New England journal of medicine.
[10] J Grogono,et al. Node negative breast cancer. , 1990, BMJ.
[11] R. Camplejohn,et al. Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Souhami,et al. A mathematical model relating response durations to amount of subclinical resistant disease. , 1991, Cancer research.
[13] J. Winstanley,et al. Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer. , 1992, British Journal of Cancer.
[14] V. Kosma,et al. DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer , 1992, International journal of cancer.
[15] R. Camplejohn. A role for proliferative measurements in clinical oncology? , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] J. Underwood. Diagnostic Molecular Pathology. A Practical Approach , 1993 .
[17] G. Del Bino,et al. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] London Scottish Cancer Trials Breast Group And Icrf Breas GUY'S HOSPITAL. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial , 1993, The Lancet.
[19] A. Howell,et al. A controlled trial of adjuvant tamoxifen, with or without prednisolone, in post-menopausal women with operable breast cancer. , 1994, British Journal of Cancer.
[20] D.,et al. Regression Models and Life-Tables , 2022 .